Literature DB >> 7846059

Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis.

W Palinski1, E Miller, J L Witztum.   

Abstract

Atherosclerotic lesions contain oxidized LDL (OxLDL), immunoglobulins, and immune-competent cells. Low levels of circulating autoantibodies against malondialdehyde (MDA)-modified lysine, an epitope of OxLDL, occur in several species, and immune complexes between such autoantibodies and OxLDL are present in lesions. To study the potential role of autoantibodies against OxLDL in the atherogenic process, we prospectively hyperimmunized LDL receptor-deficient rabbits with homologous MDA-LDL and determined the effects of this intervention on the development of atherosclerosis. Immunization with MDA-LDL generated high titers of antibodies with similar specificity as naturally occurring autoantibodies. Immunized animals showed a significant reduction in the extent of atherosclerotic lesions in the aortic tree after 6.5 months, compared with "saline"-immunized controls (48% vs. 68%, P < 0.005). Immunization with keyhole limpet hemocyanin produced no change in lesion formation. Although the mechanisms by which immunization led to a protective effect are unknown, these results suggest an important role for the immune system in modulating the atherogenic process and may indicate a novel approach for inhibiting the progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7846059      PMCID: PMC42712          DOI: 10.1073/pnas.92.3.821

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits.

Authors:  M E Rosenfeld; W Palinski; S Ylä-Herttuala; S Butler; J L Witztum
Journal:  Arteriosclerosis       Date:  1990 May-Jun

2.  Low density lipoprotein undergoes oxidative modification in vivo.

Authors:  W Palinski; M E Rosenfeld; S Ylä-Herttuala; G C Gurtner; S S Socher; S W Butler; S Parthasarathy; T E Carew; D Steinberg; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

3.  Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein.

Authors:  W Palinski; S Ylä-Herttuala; M E Rosenfeld; S W Butler; S A Socher; S Parthasarathy; L K Curtiss; J L Witztum
Journal:  Arteriosclerosis       Date:  1990 May-Jun

4.  Turnover and tissue sites of degradation of glucosylated low density lipoprotein in normal and immunized rabbits.

Authors:  O Wiklund; J L Witztum; T E Carew; R C Pittman; R L Elam; D Steinberg
Journal:  J Lipid Res       Date:  1987-09       Impact factor: 5.922

5.  Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis.

Authors:  D V Parums; D L Brown; M J Mitchinson
Journal:  Arch Pathol Lab Med       Date:  1990-04       Impact factor: 5.534

6.  Nonenzymatic glucosylation of homologous low density lipoprotein and albumin renders them immunogenic in the guinea pig.

Authors:  J L Witztum; U P Steinbrecher; M Fisher; A Kesaniemi
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

7.  Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice.

Authors:  F Liao; A Andalibi; F C deBeer; A M Fogelman; A J Lusis
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

8.  Complement receptors and regulatory proteins in human atherosclerotic lesions.

Authors:  P S Seifert; G K Hansson
Journal:  Arteriosclerosis       Date:  1989 Nov-Dec

9.  Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque.

Authors:  R Vlaicu; F Niculescu; H G Rus; A Cristea
Journal:  Atherosclerosis       Date:  1985-11       Impact factor: 5.162

10.  Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation.

Authors:  R L Griffith; G T Virella; H C Stevenson; M F Lopes-Virella
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

View more
  140 in total

Review 1.  Immune recognition of OxLDL in atherosclerosis.

Authors:  J F Kearney
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis.

Authors:  Christoph J Binder; Karsten Hartvigsen; Mi-Kyung Chang; Marina Miller; David Broide; Wulf Palinski; Linda K Curtiss; Maripat Corr; Joseph L Witztum
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

3.  Attenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells.

Authors:  Hang Pong Ng; Ramona L Burris; Shanmugam Nagarajan
Journal:  J Immunol       Date:  2011-10-31       Impact factor: 5.422

4.  Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.

Authors:  W Palinski; S Hörkkö; E Miller; U P Steinbrecher; H C Powell; L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells.

Authors:  Takayuki Kimura; Kevin Tse; Sara McArdle; Teresa Gerhardt; Jacqueline Miller; Zbigniew Mikulski; John Sidney; Alessandro Sette; Dennis Wolf; Klaus Ley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-01-13       Impact factor: 4.733

6.  Modulating atherothrombosis: is there a place for vaccines in global prevention strategies?

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

7.  Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary.

Authors:  John Hallenbeck; Gregory Del Zoppo; Tom Jacobs; Antoine Hakim; Stephen Goldman; Ursula Utz; Ahmed Hasan
Journal:  Stroke       Date:  2006-11-02       Impact factor: 7.914

Review 8.  Anti-inflammatory therapies for atherosclerosis.

Authors:  Magnus Bäck; Göran K Hansson
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

9.  4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice.

Authors:  Geoffrey D Wool; Veneracion G Cabana; John Lukens; Peter X Shaw; Christoph J Binder; Joseph L Witztum; Catherine A Reardon; Godfrey S Getz
Journal:  FASEB J       Date:  2010-09-27       Impact factor: 5.191

10.  Oxidative stress in children on hemodialysis: value of autoantibodies against oxidized low-density lipoprotein.

Authors:  Nurcan Cengiz; Esra Baskin; Nurzen Sezgin; Pinar Agras; Mehmet Haberal
Journal:  Pediatr Nephrol       Date:  2008-10-29       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.